Harnessing the Immune System Against Cancer by Targeting CD25
The shared CD25 activation mechanism on regulatory and effector T cells has been a big challenge when designing immunotherapy drugs. Cancer Research UK scientists from University College London in collaboration with Roche, have developed a new antibody that can target CD25 specifically on regulatory T cells while leaving effector T cells intact. Watch this antibody in action in this short animation.
Read the Nature paper on this area of research here.
